Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Evgen Pharma PLC- Cheshire, England-based drug development company - Announces collaboration with University of Michigan, to investigate the potential anti-tumour effects of the company's lead asset SFX-01 in colorectal cancer.
SFX-01 is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. Previous studies of the compound have shown in vivo and in vitro efficacy of the compound in a wide range of cancer cells including breast cancer, glioblastoma and certain blood cancers.
Initial results are expected at the end of 2023.
‘This new project is our fifteenth pre-clinical collaboration to date. Colorectal cancer is a relatively common disease and a cancer type we have not explored extensively. The work of Chen's group will gain valuable insights into the effects of SFX-01 in models of colorectal cancer. Building on our existing promising data on the mode of action, efficacy and tolerability of our lead asset, we continue to develop our core products to address the widest possible range of indications,’ said Chief Executive Officer Huw Jones.
Current stock price: 3.70 pence, down 3.9% on Monday
12-month change: down 52%
Copyright 2022 Alliance News Limited. All Rights Reserved.